Purpose of Review

Inflammation is involved in the initiation, progression, and destabilization of atherosclerosis. Anti-inflammatory strategies aimed at reducing residual cardiovascular (CV) risk have gained increasing interest in addition to the traditional management of risk factors. Colchicine is a potent anti-inflammatory therapy that affects the inflammasome and other targets. We will herein review the most recent evidence regarding the usefulness of colchicine in patients with coronary artery disease (CAD).

Recent Findings

Colchicine has recently been repurposed from its traditional use to a number of CV indications. The landmark COLCOT and LoDoCo2 trials have demonstrated that long-term use of colchicine was associated with a reduced rate of CV events in both acute and chronic presentations of CAD, with an overall good safety profile.

Summary

Colchicine is emerging as a valuable, safe, and cost-effective therapy in addition to standard of care for the prevention of atherothrombotic events in CAD.

中文翻译：

---

秋水仙碱治疗急性和慢性冠状动脉疾病

审查目的

炎症与动脉粥样硬化的发生、发展和不稳定有关。除了传统的风险因素管理之外，旨在降低残余心血管 (CV) 风险的抗炎策略也越来越受到关注。秋水仙碱是一种有效的抗炎疗法，可影响炎性体和其他靶标。我们将在此回顾有关秋水仙碱对冠状动脉疾病 (CAD) 患者有用的最新证据。

最近的发现

秋水仙碱最近已从其传统用途重新用于许多 CV 适应症。具有里程碑意义的 COLCOT 和 LoDoCo2 试验表明，长期使用秋水仙碱与 CAD 急性和慢性表现的心血管事件发生率降低相关，总体安全性良好。

总结

除了预防 CAD 中动脉粥样硬化血栓形成事件的标准护理之外，秋水仙碱正在成为一种有价值、安全且具有成本效益的疗法。